Results 31 to 40 of about 10,873 (203)

Forest plots of the effects between the eplerenone treatment groups and the controls.

, 2022
(A) Effect on SBP in articles comparing eplerenone to placebo/active control. (B) Effect on DBP in articles comparing eplerenone to placebo/active control.
Xiangguo Cong (12289819), Wenlong Liang (5871260), Honglei Hu (12289813), Xiaodong Zhao (327921), Shujuan Wang (30858), Xingqian Jin (12289816)   +5 more
core   +2 more sources

Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats

Clinical and Experimental Hypertension, 2020
Evidence indicates that renin-angiotensin-aldosterone system (RAS) inhibitors can protect the brain in Alzheimer’s disease and Parkinson’s disease.
Xue Wang, Yuhai Zhu, Shuanglin Wang, Zhuoqun Wang, Haonan Sun, Yujie He, Wei Yao   +6 more
doaj   +1 more source

Possible dose-dependent effect of eplerenone on intraocular pressure

Indian Journal of Ophthalmology, 2023
Purpose: Intraocular pressure (IOP) is the main modifiable risk factor for glaucoma. Current therapies target the anterior outflow of aqueous humor or its production. This study aims to demonstrate eplerenone could reduce IOP through a possible posterior
Seyedeh Mehrsa Sadat Razavi, Ramin Daneshvar   +1 more
doaj   +1 more source

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE

Кардиоваскулярная терапия и профилактика, 2015
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj   +1 more source

Eplerenone add-on treatment in resistant hypertension in peritoneal dialysis patient. A case report [PDF]

, 2023
Resistant hypertension (RH) is frequently seen in clinical practice in kidney disease patients. Mineralocorticoid receptor antagonists (MRAs) especially spironolactone are highly effective in the management of RH.
Donderski, Rafał Łukasz; Department of Nephrology, Hypertension and Internal Medicine, University Hospital No 1 in Bydgoszcz Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland, Stróżecki, Paweł; Department of Nephrology, Hypertension and Internal Medicine, University Hospital No 1 in Bydgoszcz Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland, Rafał Łukasz Donderski, Paweł Stróżecki   +3 more
core   +1 more source

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

Frontiers in Pharmacology, 2013
The mineralocorticoid receptor (MR) antagonists PF 03882845 and eplerenone were evaluated for renal protection against aldosterone mediated renal disease in uninephrectomized Sprague Dawley (SD) rats maintained on a high salt diet and receiving ...
Stephen eOrena, Stephen eOrena, Tristan eMaurer, Rena eEudy, Rena eEudy, Li eShe, Darla eDash, Paula eLoria, Mary Ellen eBanker, Vincent eBernardo, Meera eTugnait, Carlin eOkerberg, Jessie eQian, Carine M Boustany-Kari, Carine M Boustany-Kari   +14 more
doaj   +1 more source

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. [PDF]

PLoS ONE, 2011
Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD).
Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper   +4 more
doaj   +1 more source

Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division

Frontiers in Endocrinology, 2020
Introduction: Mineralocorticoid receptor (MR) activation within adipose tissue, triggers inflammation and metabolic syndrome development. The pharmacological blockade of MR provides beneficial effects for adipose tissue. Our study evaluates the impact of
Andrea Vecchiola, Andrea Vecchiola, Cristóbal A. Fuentes, Isidora Solar, Carlos F. Lagos, Maria Cecilia Opazo, Maria Cecilia Opazo, Natalia Muñoz-Durango, Natalia Muñoz-Durango, Claudia A. Riedel, Claudia A. Riedel, Gareth I. Owen, Gareth I. Owen, Alexis M. Kalergis, Alexis M. Kalergis, Alexis M. Kalergis, Carlos E. Fardella, Carlos E. Fardella, Carlos E. Fardella   +18 more
doaj   +1 more source

Oral eplerenone for the management of chronic central serous chorioretinopathy [PDF]

International Journal of Ophthalmology, 2015
AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR).
Rishi P Singh, Jonathan E Sears, Rumneek Bedi, Andrew P Schachat, Justis P Ehlers, Peter K Kaiser   +5 more
doaj   +1 more source

Postoperative Takotsubo Cardiomyopathy in a Young Woman: A Case Report. [PDF]

Clin Case Rep
Timeline of the patient's clinical course. ABSTRACT Takotsubo cardiomyopathy (TCM) can occur in young adults exposed to extreme physical stress, such as surgery, sepsis, and transfusion reactions. Mechanical recovery may precede electrical normalization, with ECG abnormalities persisting despite improved left ventricular ejection fraction (LVEF). Early
Siddiq N, Cheema ZZ, Khan SS, Arshad A, Awan AR, Shah S, Usman M.   +6 more
europepmc   +2 more sources